Stem Cell Research (Mar 2014)

Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery

  • Xuan Guan,
  • David L. Mack,
  • Claudia M. Moreno,
  • Jennifer L. Strande,
  • Julie Mathieu,
  • Yingai Shi,
  • Chad D. Markert,
  • Zejing Wang,
  • Guihua Liu,
  • Michael W. Lawlor,
  • Emily C. Moorefield,
  • Tara N. Jones,
  • James A. Fugate,
  • Mark E. Furth,
  • Charles E. Murry,
  • Hannele Ruohola-Baker,
  • Yuanyuan Zhang,
  • Luis F. Santana,
  • Martin K. Childers

DOI
https://doi.org/10.1016/j.scr.2013.12.004
Journal volume & issue
Vol. 12, no. 2
pp. 467 – 480

Abstract

Read online

The ability to extract somatic cells from a patient and reprogram them to pluripotency opens up new possibilities for personalized medicine. Induced pluripotent stem cells (iPSCs) have been employed to generate beating cardiomyocytes from a patient's skin or blood cells. Here, iPSC methods were used to generate cardiomyocytes starting from the urine of a patient with Duchenne muscular dystrophy (DMD). Urine was chosen as a starting material because it contains adult stem cells called urine-derived stem cells (USCs). USCs express the canonical reprogramming factors c-myc and klf4, and possess high telomerase activity. Pluripotency of urine-derived iPSC clones was confirmed by immunocytochemistry, RT-PCR and teratoma formation. Urine-derived iPSC clones generated from healthy volunteers and a DMD patient were differentiated into beating cardiomyocytes using a series of small molecules in monolayer culture. Results indicate that cardiomyocytes retain the DMD patient's dystrophin mutation. Physiological assays suggest that dystrophin-deficient cardiomyocytes possess phenotypic differences from normal cardiomyocytes. These results demonstrate the feasibility of generating cardiomyocytes from a urine sample and that urine-derived cardiomyocytes retain characteristic features that might be further exploited for mechanistic studies and drug discovery.